| Document |
Document Title |
|
WO/2024/081310A1 |
Described herein are engineered mammalian cells comprising a reduction in the level or function of one or more of a major histocompatibility complex (MHC) class I protein complex component, optionally, a MHC class II protein complex comp...
|
|
WO/2024/077899A1 |
Provided are a tissue dissociation solution for an Arabidopsis thaliana leaf sample and a dissociation method. The tissue dissociation solution is prepared by means of adding 1%-3% (g/mL) of cellulase and 1%-3% (g/mL) of pectinase to 8%-...
|
|
WO/2024/079644A1 |
The present invention is directed to a method for ex-vivo-engineering of cells, in particular stem cells or T cells, preferably hematopoietic stem and/or progenitor cells, mesenchymal stem cells, or T cells comprising a step of culturing...
|
|
WO/2024/078118A1 |
Provided herein, in some aspects, are methods and compositions for cell conversion. The methods may convert a cell population comprising one cell type to another cell population comprising another cell type. The converted cell types may ...
|
|
WO/2024/079480A1 |
The present invention provides novel mesenchymal stem cell (MSC)-like cells and cell populations. Associated DNA preparations, cell-free conditioned media, secretomes, extracellular vesicle populations, compositions, and uses thereof are...
|
|
WO/2024/081206A1 |
Methods and apparatus for dispensing droplets. In accordance with an implementation, an apparatus includes a dispenser, a liquid source, and a pressure source. The dispenser includes a tube having an outlet, a channel surrounding the tub...
|
|
WO/2024/081614A1 |
Provided herein are three-dimensional co-culture systems, methods of using three-dimensional co-culture systems, and kits comprising three-dimensional co-culture systems.
|
|
WO/2024/078479A1 |
The present invention relates to a heterodimeric fusion protein and the use thereof. The heterodimeric fusion protein of the present invention comprises: a first heavy chain, wherein the first heavy chain comprises a first Fc region and ...
|
|
WO/2024/081452A1 |
A composition comprising a hydrogel includes a polymer of formula (1), at least one repeating unit of which comprises BO2H2. Methods of making such hydrogels and methods of encapsulating cells using such hydrogels are also disclosed herein.
|
|
WO/2024/077376A1 |
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein....
|
|
WO/2023/086502A9 |
Described in several exemplary embodiments herein are serum replacement compositions, cell culture media containing said serum replacement compositions, and uses thereof.
|
|
WO/2024/080661A1 |
The present invention relates to vMSC, which is a stem cell that is newly identified and has angiogenic properties. vMSCs cultured under specific culture conditions and identified, according to the present invention, are novel MSCs that ...
|
|
WO/2024/081309A1 |
Described herein are engineered mammalian cells comprising a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex component, and, optionally, a MHC class II protein complex component and/...
|
|
WO/2024/080707A1 |
The present invention relates to a novel method for preparing organoid using the self-assembly of spheroid. Particularly, the organoid prepared by the preparation method of the present invention has a cup-shaped shape with a concave cent...
|
|
WO/2024/080306A1 |
According to one embodiment of the present invention, it is possible to efficiently produce a highly-active recombinant protein by expressing, in the form of a fusion protein with serum albumin (SA), a physiologically-active protein havi...
|
|
WO/2023/133593A9 |
Disclosed herein are recombinant AAV variant (e.g., variant serotype 5 (AAV5)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce adult stem cells and neurons. Viral particles contain...
|
|
WO/2024/075838A1 |
A pulmonary fibrosis model that includes a co-culture system containing alveolar organoids and pulmonary fibroblasts that express a reporter gene when converted into myofibroblasts, wherein, when the alveolar organoids are injured, the p...
|
|
WO/2024/075834A1 |
The present invention addresses the problem of providing a highly versatile method for storing and transporting a cell aggregate, the method being capable of storing and transporting the cell aggregate while maintaining the form thereof....
|
|
WO/2024/076030A1 |
The present invention relates to a method for producing platelets. The method of the present invention includes the steps of: (S1) culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells; (S2) obta...
|
|
WO/2024/077022A2 |
The present disclosure provides chimeric surfaces. The chimeric surfaces may be thin films. In various embodiments, the thin films may be disposed on a substrate. Articles of manufacture may have one or more chimeric surfaces. Also discl...
|
|
WO/2024/076963A1 |
Method and system wherein induced pluripotent stem cells quality and differentiation are evaluated using T2 magnetic resonance relaxometry.
|
|
WO/2024/077117A1 |
Disclosed generally are methods of purifying and concentrating exosomes produced in cell culture. Disclosed specifically are methods of purifying and concentrating native or engineered exosomes produced in cell culture by cell culture cl...
|
|
WO/2024/075145A1 |
The present invention relates to a human dental pulp-derived stem cell population and culture supernatant thereof, a pharmaceutical composition comprising the stem cell population, and method for producing same. Specifically, the present...
|
|
WO/2024/077145A1 |
The present disclosure in various aspects and embodiments relates to cell compositions (and methods for making or using the same) comprising hematopoietic stem cells (HSCs) and/or hematopoietic stem progenitor cells (HSPCs), where the HS...
|
|
WO/2024/075676A1 |
The present invention pertains to an agent that is for treating or preventing cerebral palsy, that contains dental pulp stem cells, and that is to be administered to a subject having a symptom of cerebral palsy.
|
|
WO/2024/074709A1 |
The present invention relates to the field of synthetic evolution, and provides with a virus-assisted evolution platform for hyper-directed evolution of phenotypes in mammalian cells.
|
|
WO/2024/077116A1 |
A pharmaceutical composition for use in promoting bone/cartilage regeneration, includes a PEDF-derived short peptide (PDSP); and mesenchymal stem cells (MSCs). The PDSP is 14-39 amino acids long. The PDSP has the amino-acid sequence sele...
|
|
WO/2024/076121A1 |
The present invention relates to immune cells co-expressing IL-15 and a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain, and to a composition for preventing or treating cancer comprising same as a...
|
|
WO/2024/074142A1 |
Provided are codon-optimized GBA1polynucleotides that encode a GCase protein, with a portion of the coding sequence deviating from the wild-type. Additionally provided are expression constructs, vectors, viral particles, or compositions ...
|
|
WO/2024/076910A2 |
Organoid culture and image-processing methods and systems are described. Such methods and systems provide the ability for high-throughput characterization of a variety of phenotypes at single-organoid resolution.
|
|
WO/2024/075722A1 |
The present invention provides: a method for culturing adhesive cells using a microcarrier coated with a polymer that exhibits a lower critical temperature within a culture vessel, wherein the method is characterized by including the fol...
|
|
WO/2024/076605A1 |
Provided herein are multilineage cardiovascular organoids and methods of generating the same. In some aspects, provided herein is a system comprising a plurality of multilineage cardiovascular organoids derived from embryoid bodies. The ...
|
|
WO/2024/077140A1 |
In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specif...
|
|
WO/2024/077153A1 |
The present disclosure provides for efficient ex vivo processes for generating megakaryocytes and/or platelets from human induced pluripotent stem cells (iPSCs). Cells and platelets generated according to the disclosure in various embodi...
|
|
WO/2024/074540A2 |
The invention relates to a genetically engineered cell and compositions comprising said cell, wherein said cell is engineered to be especially sensitive towards two or more environmental factors, to enhance the biosafety profile of said ...
|
|
WO/2024/073845A1 |
The present application relates to methods for expanding hematopoietic stem cells (HSC) and/or hematopoietic progenitor cells (HPC) ex vivo and/or in vivo. The methods comprise culturing the HSCs and/or HPCs in the presence of a selectiv...
|
|
WO/2024/077174A1 |
The present disclosure provides methods of preparing immune cells, e.g., T cells and/or NK cells, comprising contacting the cells with programmable cell-signaling scaffolds in a medium comprising at least about 5 mM potassium ion and edi...
|
|
WO/2024/077274A1 |
Provided here are cell culture system with tunable stiffness comprising a biocompatible polydimethyl siloxane substrate and a polyelectrolyte multilayer. Also provided here are methods of making and using these systems as research and/or...
|
|
WO/2024/077270A1 |
Described herein are immunoresponsive cells engineered to express cytokines and chimeric receptors. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/077295A2 |
The present disclosure provides methods, compositions, and systems for producing and using organoids comprising fibroblasts. The organoids can be generated and placed in a particular storage matrix which allows for sufficient conditions ...
|
|
WO/2024/075756A1 |
Provided is a method for producing a library containing gene-modified cells. This library is useful in the functional evaluation of a specific region of a genome and the introduction, etc., of various types of mutations (such as SNPs) to...
|
|
WO/2024/076758A1 |
Methods and composition for growth and maintenance of Oct3/4+ SOX2+ NANOG+ pluripotent stem cells (PSCs) or generation and maintenance of CD7+ CD75+ CD77+ CD 130+ F11R+ naive PSCs in cell culture comprise the use of a small molecule-base...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075941A1 |
The present invention relates to super absorbent polymer-based surface fixation technology for extracellular vesicles or cells and, more specifically, to a technology and applications thereof, the technology fixing, to the surface of a s...
|
|
WO/2024/077158A1 |
In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for ...
|
|
WO/2024/076173A1 |
Disclosed are a composition for inducing differentiation of adipose-derived stem cells into dermal papilla cells, and a differentiation method using the composition. The composition for inducing differentiation and the differentiation me...
|
|
WO/2024/077255A1 |
Transgenic bioincubators are provided having an FAH transgene or endogenous FAH modified with an inducible promoter. The inducible promoter allows for control of the expression of FAH in the presence or absence of an inducer, for purpose...
|
|
WO/2024/076329A1 |
The invention relates to an exosome-based biocompatible implant obtained by spraying exosomes obtained from stem cells onto implant materials consisting of different materials. Said exosomes are attached to the implant material at a leve...
|
|
WO/2024/076507A1 |
Methods for improving parthenogenesis efficiency by DWT1 and BABY BOOM transcription factors in plants are provided. A rice embryo trigger transcription factor BABY BOOM1 can initiate embryogenesis when expressed in the unfertilized egg ...
|
|
WO/2024/076182A1 |
The present invention relates to a medium composition for preparing a salivary gland organoid. Also, the present invention relates to: a method for preparing a salivary gland organoid, comprising a step of culturing salivary gland-derive...
|
